A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : PD-1

Search Conditions:
Search Keyword : PD-1
Search Method : Exact match.
Research Area:

Results:  
Abbreviation: PD-1
Appearance Frequency: 4942 time(s)
Long forms: 50

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
programmed death-1
(4872 times)
Neoplasms
(1631 times)
PD-L1 (1622 times)
CTLA-4 (576 times)
NSCLC (504 times)
1997 Activation-induced expression of human programmed death-1 gene in T-lymphocytes.
programmed death molecule-1
(6 times)
Allergy and Immunology
(2 times)
CTLA-4 (2 times)
RA (2 times)
aGVHD (1 time)
2009 Increased programmed death-1 molecule expression in cytomegalovirus disease and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
PDCD-1
(5 times)
Biology
(1 time)
ACT (1 time)
BC (1 time)
DEGs (1 time)
2015 Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma.
PD-L1 or programmed cell death-1
(4 times)
Neoplasms
(2 times)
PD-L1 (3 times)
ADC (1 time)
APACHE (1 time)
2017 PD-L1 Overexpression During Endotoxin Tolerance Impairs the Adaptive Immune Response in Septic Patients via HIF1alpha.
Programmed death axis 1
(3 times)
Medicine
(2 times)
T1D (3 times)
CD (1 time)
PBMC (1 time)
2016 PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?
anti-PDCD1
(2 times)
Neoplasms
(1 time)
B2M (1 time)
FSP (1 time)
MMR (1 time)
2018 High numbers of PDCD1 (PD-1)-positive T cells and B2M mutations in microsatellite-unstable colorectal cancer.
anti-program cell death -1
(2 times)
Neoplasms
(1 time)
aNSCLC (1 time)
BMI (1 time)
BOR (1 time)
2020 PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors.
PD-1hi
(2 times)
Microbiological Phenomena
(1 time)
FV (1 time)
IO (1 time)
MIBC (1 time)
2018 Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment.
PDCD1, CD279
(2 times)
Pathology
(1 time)
ALDH1 (1 time)
AML (1 time)
2017 Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.
10  programmed cell death-1 protein receptor
(2 times)
Neoplasms
(2 times)
CI (1 time)
ctDNA (1 time)
ctDNA TMB (1 time)
2016 Biomarkers for PD-1/PD-L1 Blockade Therapy inNon-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
11  programmed death 1 positive
(2 times)
Medicine
(1 time)
ICOS (2 times)
AUC (1 time)
BCL6 (1 time)
2016 [Detection of peripheral follicular helper T cells in rheumatoid arthritis].
12  protein death-1
(2 times)
Immune System Diseases
(1 time)
CTLA-4 (1 time)
ICB (1 time)
2016 PD1-Expressing T Cell Subsets Modify the Rejection Risk in Renal Transplant Patients.
13  Anti(alpha)-programmed cell death-1
(1 time)
Immunotherapy
(1 time)
DLN (1 time)
IL (1 time)
M-MDSC (1 time)
2020 Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
14  anti-PD-1 antibodies
(1 time)
Liver Neoplasms
(1 time)
LEN (1 time)
ORR (1 time)
uHCC (1 time)
2021 Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study.
15  anti-PD-1 was used to activate or block the programmed death
(1 time)
Medicine
(1 time)
CD28 (1 time)
ELISA (1 time)
IFN-gamma (1 time)
2019 PD-1/PD-L1 pathway activation restores the imbalance of Th1/Th2 and treg/Th17 cells subtypes in immune thrombocytopenic purpura patients.
16  anti-PD-L1/anti- programmed cell death 1
(1 time)
Neoplasms
(1 time)
DFS (1 time)
LNMs (1 time)
PD-L1 (1 time)
2018 Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
17  anti-programmed death-1 antibodies
(1 time)
Chemistry
(1 time)
CA (1 time)
HSA (1 time)
2021 Preparation and evaluation of dabrafenib-loaded, CD47-conjugated human serum albumin-based nanoconstructs for chemoimmunomodulation.
18  CAMPANELLIProgrammed Death 1
(1 time)
Dental Pulp Diseases
(1 time)
PD-L1 (2 times)
2020 CAMPANELLIProgrammed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis.
19  death protein 1 receptor
(1 time)
cSCC (1 time)
2020 Complete Resolution of a Large, Locally-advanced Cutaneous Squamous Cell Carcinoma with the Immune-modulating PD-1 Inhibitor Pembrolizumab.
20  death-protein 1
(1 time)
Drug Therapy
(1 time)
Ab (1 time)
CTL (1 time)
DCs (1 time)
2019 A Toll-like receptor 3 (TLR3) agonist ARNAX for therapeutic immunotherapy.
21  particular, inhibition of the antiprogrammed death-1
(1 time)
Medicine
(1 time)
CI (1 time)
CT (1 time)
EORTC (1 time)
2021 A pilot study on EORTC or PERCIST for the prediction of progression-free survival with nivolumab therapy in advanced or metastatic gastric cancers: A STROBE-compliant article.
22  particularly antiprogrammed death 1
(1 time)
Neoplasms
(1 time)
CPI (1 time)
2019 Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
23  patient was initiated on antiprogrammed-death receptor 1
(1 time)
Medicine
(1 time)
SRS (1 time)
VS (1 time)
2021 Growth arrest of a refractory vestibular schwannoma after anti-PD-1 antibody treatment.
24  patients treated with antiprogrammed death receptor-1
(1 time)
Immunotherapy
(1 time)
LDH (1 time)
MGR (1 time)
OS (1 time)
2021 Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.
25  PD-1 decoy
(1 time)
Immunity
(1 time)
PD-L1 (1 time)
2016 Enhanced Anti-tumor Reactivity of Cytotoxic T Lymphocytes Expressing PD-1 Decoy.
26  PD-1 expressed on T cells and its ligands
(1 time)
Neoplasms
(1 time)
MDSC (1 time)
TAM (1 time)
TIL (1 time)
2013 Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.
27  PD-1 expression
(1 time)
Acquired Immunodeficiency Syndrome
(1 time)
ART (1 time)
2019 T cells with high PD-1 expression are associated with lower HIV-specific immune responses despite long-term antiretroviral therapy.
28  PD-1 receptor
(1 time)
Cells
(1 time)
NK (1 time)
NPC (1 time)
PD-L1 (1 time)
2021 Radiotherapy Combined with PD-1 Inhibition Increases NK Cell Cytotoxicity towards Nasopharyngeal Carcinoma Cells.
29  PD-1 Tg
(1 time)
Biomedical Research
(1 time)
--- 2021 Overexpression of PD-1 on T cells promotes tolerance in cardiac transplantation via ICOS-dependent mechanisms.
30  PD-1.1, PD-1.3, PD-1.5, PD-1.9
(1 time)
Clinical Medicine
(1 time)
CI (1 time)
CTLA-4 (1 time)
NSCLC (1 time)
2015 Polymorphisms of co-inhibitory molecules (CTLA-4/PD-1/PD-L1) and the risk of non-small cell lung cancer in a Chinese population.
31  PD-1ECD
(1 time)
Natural Science Disciplines
(1 time)
--- 2016 High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1.
32  PD-1ex
(1 time)
Hematology
(1 time)
AML (1 time)
BiTE (1 time)
CiTE (1 time)
2018 Bifunctional PD-1 alphaCD3 alphaCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.
33  PD-L1 and its receptor
(1 time)
Hematology
(1 time)
PD-L1 (1 time)
2017 Clinical applications of PD-L1 bioassays for cancer immunotherapy.
34  PD-L1 mRNA levels were independent poor prognostic factors for OS
(1 time)
General Surgery
(1 time)
GC (1 time)
OS (1 time)
PB (1 time)
2018 Prognostic Impact of Immune-Related Gene Expression in Preoperative Peripheral Blood from Gastric Cancer Patients.
35  PD-L1 negative tumors
(1 time)
Internal Medicine
(1 time)
NENs (1 time)
PD (1 time)
TIL (1 time)
2020 Pathological Findings of the Host Immune Reaction in the Tumor Microenvironment of Gastroenteropancreatic Neuroendocrine Neoplasms.
36  pembrolizumab, an antiprogrammed cell death 1
(1 time)
Neoplasms
(1 time)
EGFR (1 time)
HNSCC (1 time)
2021 Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
37  Pembrolizumab: a novel antiprogrammed death 1
(1 time)
Pharmacy
(1 time)
--- 2015 Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma.
38  percentages of GC TFH (CXCR5(high)PD-1(high)) and CXCR5(+)programmed cell death-1
(1 time)
Allergy and Immunology
(1 time)
EF (1 time)
GC (1 time)
TFH (1 time)
2016 Germinal Center T Follicular Helper Cells Are Highly Permissive to HIV-1 and Alter Their Phenotype during Virus Replication.
39  poor response to antiprogrammed cell death-1
(1 time)
Immunotherapy
(1 time)
DOR (1 time)
GEP (1 time)
MM (1 time)
2022 Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis.
40  pPD-1A
(1 time)
Biotechnology
(1 time)
GFP (1 time)
2005 [Eukaryotic expression and functional characterization of PD-1 extracellular domain].
41  Priya Darshini-1
(1 time)
Nutritional Sciences
(1 time)
PR (1 time)
1986 Genetic regulation of carotene biosynthesis in selected tomato strains: aspects of beta-carotene biosynthesis and B gene specificity.
42  Program Death 1 receptor
(1 time)
Neoplasms
(1 time)
ALK (1 time)
EGFR (1 time)
NSCLC (1 time)
2017 Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come.
43  programmed cell death-1 inhibitor
(1 time)
Hematologic Diseases
(1 time)
ORR (1 time)
2021 The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers.
44  programmed death 1 coinhibitory receptor
(1 time)
Biomedical Research
(1 time)
AML (1 time)
LAM (1 time)
TSC (1 time)
2018 TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy.
45  programmed death 1 on T cells
(1 time)
Neoplasms
(1 time)
AEs (1 time)
CTLA-4 (1 time)
HRQoL (1 time)
2017 Health-related quality of life results from the phase III CheckMate 067 study.
46  programmed death 1 pathway
(1 time)
Neoplasms
(1 time)
PD-L1 (1 time)
2015 Anti-PD-1 therapy in melanoma.
47  Programmed death cell receptor 1
(1 time)
Allergy and Immunology
(1 time)
APC (1 time)
2011 Regulation of Trypanosoma cruzi-induced myocarditis by programmed death cell receptor 1.
48  Programmed necrosis factor 1
(1 time)
Allergy and Immunology
(1 time)
AP (1 time)
2021 PD-1/PDL1 Blockade Exacerbates Pancreatic Damage and Immune Response in a Mouse Model of Acute Pancreatitis.
49  project directorate-1
(1 time)
Animal Diseases
(1 time)
BV (1 time)
BW (1 time)
EP (1 time)
2020 Variance component analysis of growth and production traits in Vanaraja male line chickens using animal model.
50  protein 1:programmed death ligand 1
(1 time)
Molecular Biology
(1 time)
CTLA-4 (1 time)
2020 PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies.